Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients.

Hagman, Zandra LU ; Haflidadottir, Benedikta LU ; Ceder, Jens LU ; Larne, Olivia LU ; Bjartell, Anders LU ; Lilja, Hans LU orcid ; Edsjö, Anders LU and Ceder, Yvonne LU orcid (2013) In British Journal of Cancer 108(8). p.1668-1676
Abstract
Background:The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA.Methods:The expression of miR-205 is measured by qRT-PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry.Results:The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are... (More)
Background:The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA.Methods:The expression of miR-205 is measured by qRT-PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry.Results:The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are enriched in, for example, the MAPK/ERK, Toll-like receptor and IL-6 signaling pathways. We demonstrate binding of miR-205 to the 3'UTR of androgen receptor (AR) and decrease of both AR transcript and protein levels. This finding was corroborated in the patient cohort were miR-205 expression inversely correlated to AR immunostaining in malignant prostate cells and to serum levels of prostate-specific antigen, an androgen-regulated protein.Conclusion:Taken together, these findings imply that miR-205 might have therapeutic potential, especially for the castration resistant and currently untreatable form of PCa.British Journal of Cancer advance online publication, 9 April 2013; doi:10.1038/bjc.2013.131 www.bjcancer.com. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Cancer
volume
108
issue
8
pages
9 pages
publisher
Nature Publishing Group
external identifiers
  • wos:000318406400015
  • pmid:23571738
  • scopus:84877017881
  • pmid:23571738
ISSN
1532-1827
DOI
10.1038/bjc.2013.131
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Chemistry, Malmö (013016000), Molecular Medicine (013031200), Division of urological research (013243410), Division of Urological Cancers (013243420)
id
ec1c658f-67b3-4659-a7bc-f681a328f3da (old id 3733987)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23571738?dopt=Abstract
date added to LUP
2016-04-01 11:02:35
date last changed
2022-05-19 02:19:59
@article{ec1c658f-67b3-4659-a7bc-f681a328f3da,
  abstract     = {{Background:The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA.Methods:The expression of miR-205 is measured by qRT-PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry.Results:The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are enriched in, for example, the MAPK/ERK, Toll-like receptor and IL-6 signaling pathways. We demonstrate binding of miR-205 to the 3'UTR of androgen receptor (AR) and decrease of both AR transcript and protein levels. This finding was corroborated in the patient cohort were miR-205 expression inversely correlated to AR immunostaining in malignant prostate cells and to serum levels of prostate-specific antigen, an androgen-regulated protein.Conclusion:Taken together, these findings imply that miR-205 might have therapeutic potential, especially for the castration resistant and currently untreatable form of PCa.British Journal of Cancer advance online publication, 9 April 2013; doi:10.1038/bjc.2013.131 www.bjcancer.com.}},
  author       = {{Hagman, Zandra and Haflidadottir, Benedikta and Ceder, Jens and Larne, Olivia and Bjartell, Anders and Lilja, Hans and Edsjö, Anders and Ceder, Yvonne}},
  issn         = {{1532-1827}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{1668--1676}},
  publisher    = {{Nature Publishing Group}},
  series       = {{British Journal of Cancer}},
  title        = {{miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients.}},
  url          = {{http://dx.doi.org/10.1038/bjc.2013.131}},
  doi          = {{10.1038/bjc.2013.131}},
  volume       = {{108}},
  year         = {{2013}},
}